News

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

  mRNA Diagnostic Index to Measure Drug Treatment Response Vancouver, British Columbia – June 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its
Read More »

Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

  Vancouver, British Columbia – June 09, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central
Read More »

Nova Mentis Receives Controlled Substances Export Approval From The U.S DEA For The Company’s Proprietary Psilocybin Drug NM 1001

  Vancouver, British Columbia – June 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it received the required controlled substances export approval from the U.S. Drug
Read More »

Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team

  Vancouver, British Columbia – May 12, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to welcome John Molinaro, a Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy, to its Scientific
Read More »

Nova Mentis Psilocybin Manufacturer Receives Approved Health Canada Importation Permit

Phase 2A Microdose Clinical Study Capsules to be Manufactured     Vancouver, British Columbia – May 4, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the Company
Read More »

Nova Mentis Sees Rapid Enrollment in Autism Study

Databank to focus on mRNA neuroinflammatory markers and serotonin neuro-transmitters     Vancouver, British Columbia – April 28, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is excited to announce that
Read More »